JP2014523901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523901A5 JP2014523901A5 JP2014519057A JP2014519057A JP2014523901A5 JP 2014523901 A5 JP2014523901 A5 JP 2014523901A5 JP 2014519057 A JP2014519057 A JP 2014519057A JP 2014519057 A JP2014519057 A JP 2014519057A JP 2014523901 A5 JP2014523901 A5 JP 2014523901A5
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- fluoro
- phenyl
- chloro
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000003839 salts Chemical group 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 5
- BBLXLHYPDOMJMO-UHFFFAOYSA-N 5-(butan-2-ylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound CCC(C)NS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 BBLXLHYPDOMJMO-UHFFFAOYSA-N 0.000 claims description 3
- DIBFYUJKGFSYSJ-UHFFFAOYSA-N 5-(cyclohexylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCCC2)=CC=C1F DIBFYUJKGFSYSJ-UHFFFAOYSA-N 0.000 claims description 3
- ZSAVPNCDVFOTNN-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCC2)=CC=C1F ZSAVPNCDVFOTNN-UHFFFAOYSA-N 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 239000000562 conjugate Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- YTTWDIOCTVIQJQ-UHFFFAOYSA-N 2-bromo-5-(cyclohexylsulfamoyl)-n-phenylbenzamide Chemical compound BrC1=CC=C(S(=O)(=O)NC2CCCCC2)C=C1C(=O)NC1=CC=CC=C1 YTTWDIOCTVIQJQ-UHFFFAOYSA-N 0.000 claims 1
- FNUCPIHCITUGQE-UHFFFAOYSA-N 2-chloro-n-(3-methylphenyl)-5-sulfamoylbenzamide Chemical compound CC1=CC=CC(NC(=O)C=2C(=CC=C(C=2)S(N)(=O)=O)Cl)=C1 FNUCPIHCITUGQE-UHFFFAOYSA-N 0.000 claims 1
- NRRAAVBIZGRKFF-UHFFFAOYSA-N 2-fluoro-5-[(4-fluorophenyl)sulfamoyl]-n-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NC=2C=CC(F)=CC=2)F)=C1 NRRAAVBIZGRKFF-UHFFFAOYSA-N 0.000 claims 1
- ZKYVPYFRGZNHJT-UHFFFAOYSA-N 2-fluoro-5-[(4-methoxyphenyl)sulfamoyl]-n-(3-methylphenyl)benzamide Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(C)C=CC=2)=C1 ZKYVPYFRGZNHJT-UHFFFAOYSA-N 0.000 claims 1
- MPCMNARIWULMFJ-UHFFFAOYSA-N 2-fluoro-n-(3-fluorophenyl)-5-(furan-2-ylmethylsulfamoyl)benzamide Chemical compound FC1=CC=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NCC=2OC=CC=2)F)=C1 MPCMNARIWULMFJ-UHFFFAOYSA-N 0.000 claims 1
- PBAWFYZFSXYUOS-UHFFFAOYSA-N 3-(azepan-1-ylsulfonyl)-n-benzyl-4-chlorobenzamide Chemical compound ClC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCCCCC1 PBAWFYZFSXYUOS-UHFFFAOYSA-N 0.000 claims 1
- KEZNVHQUQCVDAX-UHFFFAOYSA-N 3-(cyclohexylsulfamoyl)-4-methyl-n-phenylbenzamide Chemical compound CC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1S(=O)(=O)NC1CCCCC1 KEZNVHQUQCVDAX-UHFFFAOYSA-N 0.000 claims 1
- WFDUMBOKYBAJST-UHFFFAOYSA-N 3-(cyclopentylsulfamoyl)-4-fluoro-n-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C=C(C(F)=CC=2)S(=O)(=O)NC2CCCC2)=C1 WFDUMBOKYBAJST-UHFFFAOYSA-N 0.000 claims 1
- TVUAZFKFLYTZMI-UHFFFAOYSA-N 3-(cyclopentylsulfamoyl)-n-phenylbenzamide Chemical compound C=1C=CC(S(=O)(=O)NC2CCCC2)=CC=1C(=O)NC1=CC=CC=C1 TVUAZFKFLYTZMI-UHFFFAOYSA-N 0.000 claims 1
- DPONBEDTMNFWFV-UHFFFAOYSA-N 3-(diethylsulfamoyl)-n-phenylbenzamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC=CC=2)=C1 DPONBEDTMNFWFV-UHFFFAOYSA-N 0.000 claims 1
- VFQPLEJOOLNBTH-UHFFFAOYSA-N 3-(furan-2-ylmethylsulfamoyl)-n-phenylbenzamide Chemical compound C=1C=CC(S(=O)(=O)NCC=2OC=CC=2)=CC=1C(=O)NC1=CC=CC=C1 VFQPLEJOOLNBTH-UHFFFAOYSA-N 0.000 claims 1
- KIQGAHCODFLQIZ-UHFFFAOYSA-N 3-[(2-methylphenyl)sulfamoyl]-n-phenylbenzamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC=CC=2)=C1 KIQGAHCODFLQIZ-UHFFFAOYSA-N 0.000 claims 1
- YVEKYUJVYNNGIM-UHFFFAOYSA-N 3-[(3-methylphenyl)sulfamoyl]-n-phenylbenzamide Chemical compound CC1=CC=CC(NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NC=2C=CC=CC=2)=C1 YVEKYUJVYNNGIM-UHFFFAOYSA-N 0.000 claims 1
- QPCNWXKARWHIMY-UHFFFAOYSA-N 3-[[3-(benzylcarbamoyl)phenyl]sulfonylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NCC=2C=CC=CC=2)=C1 QPCNWXKARWHIMY-UHFFFAOYSA-N 0.000 claims 1
- SDQANSXWGDCZHL-UHFFFAOYSA-N 3-[benzyl(ethyl)sulfamoyl]-n-(3,4-difluorophenyl)-4-fluorobenzamide Chemical compound C=1C(C(=O)NC=2C=C(F)C(F)=CC=2)=CC=C(F)C=1S(=O)(=O)N(CC)CC1=CC=CC=C1 SDQANSXWGDCZHL-UHFFFAOYSA-N 0.000 claims 1
- MAPCCQHYDIBUOE-UHFFFAOYSA-N 4-chloro-3-(cyclohexylsulfamoyl)-n-(4-fluorophenyl)benzamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC=C(Cl)C(S(=O)(=O)NC2CCCCC2)=C1 MAPCCQHYDIBUOE-UHFFFAOYSA-N 0.000 claims 1
- QDNZYNPFXOYFFH-UHFFFAOYSA-N 4-chloro-n-(3-fluorophenyl)-3-morpholin-4-ylsulfonylbenzamide Chemical compound FC1=CC=CC(NC(=O)C=2C=C(C(Cl)=CC=2)S(=O)(=O)N2CCOCC2)=C1 QDNZYNPFXOYFFH-UHFFFAOYSA-N 0.000 claims 1
- TWVONQXJEQBVIQ-UHFFFAOYSA-N 4-chloro-n-(4-fluorophenyl)-3-piperidin-1-ylsulfonylbenzamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCC2)=C1 TWVONQXJEQBVIQ-UHFFFAOYSA-N 0.000 claims 1
- JSZVDCAAQWXMCQ-UHFFFAOYSA-N 4-chloro-n-phenyl-3-thiomorpholin-4-ylsulfonylbenzamide Chemical compound ClC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCSCC1 JSZVDCAAQWXMCQ-UHFFFAOYSA-N 0.000 claims 1
- WPMSBSXBLNTLGB-UHFFFAOYSA-N 4-fluoro-3-(furan-2-ylmethylsulfamoyl)-n-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C=C(C(F)=CC=2)S(=O)(=O)NCC=2OC=CC=2)=C1 WPMSBSXBLNTLGB-UHFFFAOYSA-N 0.000 claims 1
- ZHWVUVOALLPLDK-UHFFFAOYSA-N 4-fluoro-3-sulfamoyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 ZHWVUVOALLPLDK-UHFFFAOYSA-N 0.000 claims 1
- QSNRCGNYLFXFOX-UHFFFAOYSA-N 4-methyl-n-phenyl-3-piperidin-1-ylsulfonylbenzamide Chemical compound CC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCCCC1 QSNRCGNYLFXFOX-UHFFFAOYSA-N 0.000 claims 1
- LQSVIKKUGQAEBP-UHFFFAOYSA-N 5-(azepan-1-ylsulfonyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)N2CCCCCC2)=CC=C1F LQSVIKKUGQAEBP-UHFFFAOYSA-N 0.000 claims 1
- XOYCHWHQJKTPKY-UHFFFAOYSA-N 5-(benzylsulfamoyl)-2-chloro-n-phenylbenzamide Chemical compound ClC1=CC=C(S(=O)(=O)NCC=2C=CC=CC=2)C=C1C(=O)NC1=CC=CC=C1 XOYCHWHQJKTPKY-UHFFFAOYSA-N 0.000 claims 1
- KYKKHEPFCUUKQU-UHFFFAOYSA-N 5-(benzylsulfamoyl)-n-(3-chloro-4-fluorophenyl)-2-fluorobenzamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCC=2C=CC=CC=2)=CC=C1F KYKKHEPFCUUKQU-UHFFFAOYSA-N 0.000 claims 1
- OGAJDFDTOUWQTL-UHFFFAOYSA-N 5-(cycloheptylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCCCC2)=CC=C1F OGAJDFDTOUWQTL-UHFFFAOYSA-N 0.000 claims 1
- VWXZMUJTTIZYMN-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-2-fluoro-n-(4-fluorophenyl)benzamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCC2)=CC=C1F VWXZMUJTTIZYMN-UHFFFAOYSA-N 0.000 claims 1
- COIGKRMQVNURRO-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-n-(3,5-dichlorophenyl)-2-fluorobenzamide Chemical compound FC1=CC=C(S(=O)(=O)NC2CCCC2)C=C1C(=O)NC1=CC(Cl)=CC(Cl)=C1 COIGKRMQVNURRO-UHFFFAOYSA-N 0.000 claims 1
- XEDMIPPPLRMEDD-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-n-(3,5-dimethylphenyl)-2-fluorobenzamide Chemical compound CC1=CC(C)=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NC2CCCC2)F)=C1 XEDMIPPPLRMEDD-UHFFFAOYSA-N 0.000 claims 1
- ZHJPAXADDOFOOA-UHFFFAOYSA-N 5-(diethylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 ZHJPAXADDOFOOA-UHFFFAOYSA-N 0.000 claims 1
- SXWOBZCNPAWIMT-UHFFFAOYSA-N 5-[(2-chlorophenyl)methylsulfamoyl]-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCC=2C(=CC=CC=2)Cl)=CC=C1F SXWOBZCNPAWIMT-UHFFFAOYSA-N 0.000 claims 1
- ANYRROIODVIJMW-UHFFFAOYSA-N 5-[2-(cyclohexen-1-yl)ethylsulfamoyl]-n-(3,5-dimethylphenyl)-2-fluorobenzamide Chemical compound CC1=CC(C)=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NCCC=2CCCCC=2)F)=C1 ANYRROIODVIJMW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- JWGKMOUUSKAEMG-UHFFFAOYSA-N methyl 5-[[[4-chloro-3-(phenylcarbamoyl)phenyl]sulfonylamino]methyl]furan-2-carboxylate Chemical compound O1C(C(=O)OC)=CC=C1CNS(=O)(=O)C1=CC=C(Cl)C(C(=O)NC=2C=CC=CC=2)=C1 JWGKMOUUSKAEMG-UHFFFAOYSA-N 0.000 claims 1
- YTEPBXQPDFTBDV-UHFFFAOYSA-N n-(3,4-difluorophenyl)-2-fluoro-5-(2-phenylethylsulfamoyl)benzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCCC=2C=CC=CC=2)=CC=C1F YTEPBXQPDFTBDV-UHFFFAOYSA-N 0.000 claims 1
- KVUYYMSVYWAUHA-UHFFFAOYSA-N n-(3,4-difluorophenyl)-4-fluoro-3-[(2-methylcyclohexyl)sulfamoyl]benzamide Chemical compound CC1CCCCC1NS(=O)(=O)C1=CC(C(=O)NC=2C=C(F)C(F)=CC=2)=CC=C1F KVUYYMSVYWAUHA-UHFFFAOYSA-N 0.000 claims 1
- GNYLBBUBZYNWMA-UHFFFAOYSA-N n-(3,4-difluorophenyl)-5-(dipropylsulfamoyl)-2-fluorobenzamide Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 GNYLBBUBZYNWMA-UHFFFAOYSA-N 0.000 claims 1
- RNVYVZZFNFIOGY-UHFFFAOYSA-N n-(3,5-dichlorophenyl)-2-fluoro-5-(furan-2-ylmethylsulfamoyl)benzamide Chemical compound FC1=CC=C(S(=O)(=O)NCC=2OC=CC=2)C=C1C(=O)NC1=CC(Cl)=CC(Cl)=C1 RNVYVZZFNFIOGY-UHFFFAOYSA-N 0.000 claims 1
- SQXYIAWQRSLCGK-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-2-fluoro-5-(furan-2-ylmethylsulfamoyl)benzamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCC=2OC=CC=2)=CC=C1F SQXYIAWQRSLCGK-UHFFFAOYSA-N 0.000 claims 1
- GGBVCFRVKITRFL-UHFFFAOYSA-N n-(3-chlorophenyl)-2-fluoro-5-(2-phenylethylsulfamoyl)benzamide Chemical compound FC1=CC=C(S(=O)(=O)NCCC=2C=CC=CC=2)C=C1C(=O)NC1=CC=CC(Cl)=C1 GGBVCFRVKITRFL-UHFFFAOYSA-N 0.000 claims 1
- NPEYKKPRQOFFDQ-UHFFFAOYSA-N n-(3-chlorophenyl)-4-fluoro-3-(pyridin-3-ylmethylsulfamoyl)benzamide Chemical compound FC1=CC=C(C(=O)NC=2C=C(Cl)C=CC=2)C=C1S(=O)(=O)NCC1=CC=CN=C1 NPEYKKPRQOFFDQ-UHFFFAOYSA-N 0.000 claims 1
- YIGUUMSVCOYTDS-UHFFFAOYSA-N n-(3-chlorophenyl)-5-[2-(cyclohexen-1-yl)ethylsulfamoyl]-2-fluorobenzamide Chemical compound FC1=CC=C(S(=O)(=O)NCCC=2CCCCC=2)C=C1C(=O)NC1=CC=CC(Cl)=C1 YIGUUMSVCOYTDS-UHFFFAOYSA-N 0.000 claims 1
- HGYFGBSBOAUQHG-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(diethylsulfamoyl)benzamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC(Cl)=CC=2)=C1 HGYFGBSBOAUQHG-UHFFFAOYSA-N 0.000 claims 1
- MCWYIVFETHLTHK-UHFFFAOYSA-N n-(4-chlorophenyl)-3-[(2-chlorophenyl)methylsulfamoyl]-4-fluorobenzamide Chemical compound FC1=CC=C(C(=O)NC=2C=CC(Cl)=CC=2)C=C1S(=O)(=O)NCC1=CC=CC=C1Cl MCWYIVFETHLTHK-UHFFFAOYSA-N 0.000 claims 1
- YAFODRLJFSCWHU-UHFFFAOYSA-N n-(4-chlorophenyl)-3-[(2-methylphenyl)sulfamoyl]benzamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC(Cl)=CC=2)=C1 YAFODRLJFSCWHU-UHFFFAOYSA-N 0.000 claims 1
- QMHDIYFUNSUQKI-UHFFFAOYSA-N n-(4-chlorophenyl)-3-[(3-fluorophenyl)sulfamoyl]benzamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 QMHDIYFUNSUQKI-UHFFFAOYSA-N 0.000 claims 1
- CKYXLFLJAUDXPD-UHFFFAOYSA-N n-(4-chlorophenyl)-5-[2-(3,4-dimethoxyphenyl)ethylsulfamoyl]-2-fluorobenzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=CC(Cl)=CC=2)=C1 CKYXLFLJAUDXPD-UHFFFAOYSA-N 0.000 claims 1
- ZMBJURWSFGFJRY-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-4-fluoro-3-sulfamoylbenzamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC(C(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)=C1 ZMBJURWSFGFJRY-UHFFFAOYSA-N 0.000 claims 1
- QPISBSFLDIZASE-UHFFFAOYSA-N n-benzyl-3-(benzylsulfamoyl)-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1S(=O)(=O)NCC1=CC=CC=C1 QPISBSFLDIZASE-UHFFFAOYSA-N 0.000 claims 1
- MQCJWNAWLZTGQX-UHFFFAOYSA-N n-benzyl-4-bromo-3-(diethylsulfamoyl)benzamide Chemical compound C1=C(Br)C(S(=O)(=O)N(CC)CC)=CC(C(=O)NCC=2C=CC=CC=2)=C1 MQCJWNAWLZTGQX-UHFFFAOYSA-N 0.000 claims 1
- DCADFUUGMOJXGT-UHFFFAOYSA-N n-benzyl-4-chloro-3-piperidin-1-ylsulfonylbenzamide Chemical compound ClC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCCCC1 DCADFUUGMOJXGT-UHFFFAOYSA-N 0.000 claims 1
- DQBFOWJYVZUYLC-UHFFFAOYSA-N n-benzyl-4-methyl-3-(4-methylpiperidin-1-yl)sulfonylbenzamide Chemical compound C1CC(C)CCN1S(=O)(=O)C1=CC(C(=O)NCC=2C=CC=CC=2)=CC=C1C DQBFOWJYVZUYLC-UHFFFAOYSA-N 0.000 claims 1
- RPVXKBFDFCOLQP-UHFFFAOYSA-N n-phenyl-3-(pyridin-3-ylmethylsulfamoyl)benzamide Chemical compound C=1C=CC(S(=O)(=O)NCC=2C=NC=CC=2)=CC=1C(=O)NC1=CC=CC=C1 RPVXKBFDFCOLQP-UHFFFAOYSA-N 0.000 claims 1
- GJXPMGCXUXSFJW-UHFFFAOYSA-N n-phenyl-3-sulfamoylbenzamide Chemical compound NS(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC=CC=2)=C1 GJXPMGCXUXSFJW-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 3
- CISMZCVQNVNWJW-UHFFFAOYSA-N 5-chlorosulfonyl-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC(S(Cl)(=O)=O)=CC=C1F CISMZCVQNVNWJW-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LJMXGSOXXVIIBX-UHFFFAOYSA-N 5-(butan-2-ylsulfamoyl)-2-fluorobenzoic acid Chemical compound CCC(C)NS(=O)(=O)C1=CC=C(F)C(C(O)=O)=C1 LJMXGSOXXVIIBX-UHFFFAOYSA-N 0.000 description 1
- TVMQMTHQSPBXJO-UHFFFAOYSA-N 5-(cyclohexylsulfamoyl)-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(S(=O)(=O)NC2CCCCC2)=C1 TVMQMTHQSPBXJO-UHFFFAOYSA-N 0.000 description 1
- FWZLBJWLCHVGSO-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(S(=O)(=O)NC2CCCC2)=C1 FWZLBJWLCHVGSO-UHFFFAOYSA-N 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- -1 patches Substances 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503830P | 2011-07-01 | 2011-07-01 | |
| US61/503,830 | 2011-07-01 | ||
| PCT/US2012/044775 WO2013006394A1 (en) | 2011-07-01 | 2012-06-29 | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016143481A Division JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523901A JP2014523901A (ja) | 2014-09-18 |
| JP2014523901A5 true JP2014523901A5 (enExample) | 2015-08-20 |
| JP5977347B2 JP5977347B2 (ja) | 2016-08-24 |
Family
ID=47437368
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519057A Expired - Fee Related JP5977347B2 (ja) | 2011-07-01 | 2012-06-29 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| JP2016143481A Expired - Fee Related JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| JP2019077562A Pending JP2019151639A (ja) | 2011-07-01 | 2019-04-16 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016143481A Expired - Fee Related JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| JP2019077562A Pending JP2019151639A (ja) | 2011-07-01 | 2019-04-16 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9399619B2 (enExample) |
| EP (2) | EP2726459B1 (enExample) |
| JP (3) | JP5977347B2 (enExample) |
| CN (2) | CN103889953B (enExample) |
| WO (1) | WO2013006394A1 (enExample) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| KR101939710B1 (ko) * | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| CN104797561B (zh) | 2012-08-28 | 2017-03-01 | 爱尔兰詹森科学公司 | 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途 |
| UY34993A (es) * | 2012-08-28 | 2014-02-28 | Janssen R & D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| CA2896554C (en) * | 2012-12-27 | 2019-11-05 | Drexel University | Novel antiviral agents against hbv infection |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| JP6419155B2 (ja) * | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用 |
| HRP20181863T1 (hr) * | 2013-05-17 | 2018-12-28 | Janssen Sciences Ireland Uc | Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| JO3583B1 (ar) * | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| NO3024819T3 (enExample) * | 2013-07-25 | 2018-07-21 | ||
| MX368158B (es) * | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| HK1223094A1 (zh) | 2013-11-14 | 2017-07-21 | Novira Therapeutics Inc. | 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法 |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) * | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| DK3102572T3 (en) * | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| CN110437153A (zh) * | 2014-03-13 | 2019-11-12 | 美国印第安纳大学研究和技术公司 | 乙型肝炎核心蛋白变构调节剂 |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| EP3139954A4 (en) * | 2014-05-09 | 2018-02-28 | Indiana University Research and Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
| ES2874579T3 (es) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| US9765050B2 (en) * | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
| HK1247147A1 (zh) | 2015-03-19 | 2018-09-21 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10273228B2 (en) | 2015-04-17 | 2019-04-30 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| TWI721016B (zh) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| KR101857714B1 (ko) * | 2016-02-05 | 2018-05-15 | 연세대학교 산학협력단 | 신규 아미드 화합물 및 이의 용도 |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| AU2017231817B2 (en) | 2016-03-09 | 2021-02-25 | Emory University | Elimination of hepatitis B virus with antiviral agents |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| SG11201810834WA (en) | 2016-06-10 | 2018-12-28 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| MA45999A (fr) | 2016-08-22 | 2019-06-26 | Arbutus Biopharma Corp | Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CA3037151A1 (en) | 2016-09-15 | 2018-03-22 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
| CN116751200A (zh) | 2016-11-07 | 2023-09-15 | 爱彼特生物制药公司 | 含有取代的吡啶酮的三环化合物以及使用其的方法 |
| WO2018086530A1 (zh) * | 2016-11-08 | 2018-05-17 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
| CA3048278A1 (en) * | 2017-02-07 | 2018-08-16 | Janssen Pharmaceutica Nv | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| AU2018227811A1 (en) | 2017-03-02 | 2019-09-19 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| SG11201908475RA (en) | 2017-03-13 | 2019-10-30 | Assembly Biosciences Inc | Process for making hepatitis b core protein modulators |
| US11098010B2 (en) | 2017-03-21 | 2021-08-24 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| CN108794487B (zh) | 2017-05-04 | 2020-11-10 | 上海长森药业有限公司 | 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途 |
| EP3645516A4 (en) | 2017-06-27 | 2021-07-07 | Janssen Pharmaceutica NV | HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS |
| CN109251212A (zh) | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
| CN109251158B (zh) * | 2017-07-14 | 2023-05-23 | 上海长森药业有限公司 | 硫脒酰胺类化合物及其用于乙型肝炎治疗的用途 |
| EA202090514A1 (ru) | 2017-08-28 | 2020-06-24 | Энанта Фармасьютикалс, Инк. | Противовирусное средство против гепатита в |
| TW201912153A (zh) * | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 |
| BR112020008765A2 (pt) | 2017-11-02 | 2020-10-20 | Aicuris Gmbh & Co. Kg | indol-2-carboxamidas pirazolo-piperidina substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) |
| GEAP202115351A (en) | 2017-11-02 | 2021-12-10 | Aicuris Gmbh & Co Kg | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
| EP3712139A4 (en) * | 2017-11-16 | 2021-05-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | ANTIHBV TETRAHYDROISOXAZOLO [4,3-C] PYRIDINE COMPOUNDS |
| US20210079015A1 (en) | 2017-11-17 | 2021-03-18 | Novartis Ag | Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2019118358A1 (en) | 2017-12-11 | 2019-06-20 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| EP3759110A1 (en) | 2018-02-28 | 2021-01-06 | Novartis AG | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
| JP2021515769A (ja) | 2018-03-14 | 2021-06-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合調節剤の投薬レジメン |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CA3093851A1 (en) | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
| WO2019206072A1 (zh) * | 2018-04-24 | 2019-10-31 | 浙江海正药业股份有限公司 | 磺酰胺芳基甲酰胺衍生物及其制备方法和用途 |
| KR20210019489A (ko) | 2018-06-11 | 2021-02-22 | 베나토알엑스 파마슈티컬스, 인크. | B형 간염 캡시드 조립 조절제 |
| EP3597637A1 (en) | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Inhibitors of hepatitis b virus |
| EP3597653A1 (en) | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Cyclic inhibitors of hepatitis b virus |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| CN108997176B (zh) * | 2018-07-27 | 2021-07-02 | 温州医科大学 | 一种4-氯-n-取代苯基-3-磺酰氨基苯甲酰胺类化合物及其制备和抗肿瘤应用 |
| CN108863860B (zh) * | 2018-07-27 | 2021-08-06 | 温州医科大学 | 一种n-取代苯基-3-磺酰氨基苯甲酰胺类化合物及其制备和抗乳腺癌活性的应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| EP3608326A1 (en) | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
| CA3113235A1 (en) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CA3113109A1 (en) * | 2018-10-05 | 2020-04-09 | Emory University | Monomer and multimeric anti-hbv agents |
| US11560370B1 (en) | 2018-10-22 | 2023-01-24 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
| WO2020087107A1 (en) | 2018-10-31 | 2020-05-07 | The University Of Sydney | Compositions and methods for treating viral infections |
| PY1991606A (es) | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb) |
| PY1991601A (es) | 2018-11-02 | 2020-11-02 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| PY1991608A (es) | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazina activas contra el virus de la hepatitis b (vhb) |
| TW202031666A (zh) | 2018-11-02 | 2020-09-01 | 德商艾庫瑞斯公司 | 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-噻唑并[5,4-c]吡啶脲活性劑 |
| UY38436A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| PY1991611A (es) | 2018-11-02 | 2022-03-14 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| TW202415643A (zh) | 2018-12-12 | 2024-04-16 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| CN111434665B (zh) | 2019-01-11 | 2023-03-10 | 上海长森药业有限公司 | 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
| US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| KR102933784B1 (ko) | 2019-04-03 | 2026-03-06 | 알리고스 테라퓨틱스 인코포레이티드 | 피롤 화합물 |
| CN113748113A (zh) | 2019-04-30 | 2021-12-03 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物 |
| CU20210090A7 (es) | 2019-04-30 | 2022-06-06 | Aicuris Gmbh & Co Kg | Compuestos derivados de oxalil piperazinas activos contra el virus de la hepatitis b (vhb) |
| EP3962912A1 (en) | 2019-04-30 | 2022-03-09 | AiCuris GmbH & Co. KG | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
| WO2020221826A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
| US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| EP3825318A1 (en) | 2019-11-25 | 2021-05-26 | Promidis S.r.l. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| UY38705A (es) | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| EP3741762A1 (en) | 2019-05-23 | 2020-11-25 | Irbm S.P.A. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| SG11202112590WA (en) | 2019-05-24 | 2021-12-30 | Assembly Biosciences Inc | Pharmaceutical compositions for the treatment of hbv |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) * | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| KR20220119052A (ko) | 2019-12-20 | 2022-08-26 | 아뷰터스 바이오파마 코포레이션 | 합성 공정 및 중간체 |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN111349056B (zh) * | 2020-04-16 | 2022-08-02 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
| CN111393391B (zh) * | 2020-04-16 | 2022-07-26 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
| WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2021216661A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| US20230295096A1 (en) | 2020-04-22 | 2023-09-21 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| CN115843294B (zh) | 2020-04-22 | 2026-02-10 | 组装生物科学股份有限公司 | 用于治疗hbv的5元杂芳基甲酰胺化合物 |
| WO2023069545A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069544A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069547A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| US20250163009A1 (en) | 2022-02-25 | 2025-05-22 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| CN115677545B (zh) * | 2022-10-28 | 2024-03-15 | 潍坊医学院 | 一种抗hbv磺胺苯甲酰胺类衍生物及其制备方法和应用 |
| WO2025043094A1 (en) | 2023-08-23 | 2025-02-27 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2026038156A1 (en) | 2024-08-15 | 2026-02-19 | Assembly Biosciences, Inc. | Novel crystalline forms |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US422547A (en) * | 1890-03-04 | Knife | ||
| US3055905A (en) | 1958-03-04 | 1962-09-25 | Geigy Chem Corp | New sulphamyl benzamides |
| GB912060A (en) | 1960-05-09 | 1962-12-05 | British Drug Houses Ltd | 4-chloro-3-sulphamylbenzanilides |
| GB921520A (en) | 1960-10-10 | 1963-03-20 | British Drug Houses Ltd | 4-fluoro and 4-bromo-3-sulphamylbenzanilides |
| US3602786A (en) * | 1970-06-22 | 1971-08-31 | Georgy Ignatievich Izhelya | Induction linear electric motor |
| US4115155A (en) * | 1974-05-03 | 1978-09-19 | Bethlehem Steel Corporation | Low carbon high yield and tensile strength steel and method of manufacture |
| GB9109557D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| JPH0959236A (ja) | 1995-08-23 | 1997-03-04 | Dai Ichi Seiyaku Co Ltd | ベンズアミド化合物 |
| US5939423A (en) * | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
| GB9800750D0 (en) | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| WO2006044645A2 (en) * | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
| US20080021063A1 (en) * | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
| US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
| WO2008022171A1 (en) * | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
| KR20100031528A (ko) * | 2007-06-01 | 2010-03-22 | 더 트러스티즈 오브 프린스턴 유니버시티 | 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료 |
| WO2009018219A2 (en) * | 2007-07-28 | 2009-02-05 | University Of Chicago | Methods and compositions for modulating rad51 and homologous recombination |
| AU2008281877A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of CNS disorders |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20100009970A1 (en) | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| US8420823B2 (en) * | 2008-04-24 | 2013-04-16 | Msd K.K. | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient |
| FR2933698A1 (fr) * | 2008-07-09 | 2010-01-15 | Servier Lab | Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| KR101939710B1 (ko) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| JP6134338B2 (ja) * | 2012-02-29 | 2017-05-24 | バルーク エス．ブルームバーグ インスティテュート | Ｂ型肝炎ウイルス共有結合閉環状ｄｎａ形成の阻害剤およびそれらの使用方法 |
-
2012
- 2012-06-29 JP JP2014519057A patent/JP5977347B2/ja not_active Expired - Fee Related
- 2012-06-29 CN CN201280039363.5A patent/CN103889953B/zh not_active Expired - Fee Related
- 2012-06-29 EP EP12807810.2A patent/EP2726459B1/en active Active
- 2012-06-29 CN CN201610312350.0A patent/CN106166157B/zh not_active Expired - Fee Related
- 2012-06-29 US US14/130,140 patent/US9399619B2/en active Active
- 2012-06-29 WO PCT/US2012/044775 patent/WO2013006394A1/en not_active Ceased
- 2012-06-29 EP EP16174324.0A patent/EP3085368A1/en not_active Withdrawn
-
2015
- 2015-12-18 US US14/975,239 patent/US9758477B2/en active Active
-
2016
- 2016-07-21 JP JP2016143481A patent/JP6516705B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-21 US US15/656,769 patent/US20170320818A1/en not_active Abandoned
-
2019
- 2019-04-16 JP JP2019077562A patent/JP2019151639A/ja active Pending
- 2019-07-02 US US16/459,665 patent/US20190337891A1/en not_active Abandoned
-
2020
- 2020-11-23 US US17/101,852 patent/US20210070703A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10995064B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | |
| JP6409001B2 (ja) | Ｈｂｖ感染に対する新規抗ウイルス剤 | |
| JP5977347B2 (ja) | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 | |
| JP6271806B2 (ja) | ウイルス静止化合物としての抗炎症剤 | |
| JP5399237B2 (ja) | ヒトパピローマウイルス阻害剤としてのピペリジン誘導体 | |
| JP2018065817A (ja) | 抗ウイルス活性を有するメタンチオン化合物 | |
| CN115916345B (zh) | 吡咯并吡啶衍生物及其用途 | |
| US9951058B2 (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| CA2727911A1 (fr) | Phenyl-alkyl-piperazines ayant une activite modulatrice du tnf | |
| JP5547082B2 (ja) | 新規なヒトパピローマウイルス阻害剤およびそれを含有する医薬組成物 | |
| CN105263926B (zh) | 苯并噻吩化合物 | |
| HK40129041A (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| HK40059923A (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| HK40059923B (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| CN120923428A (zh) | 流感病毒核酸内切酶抑制剂及其应用 | |
| US20160280669A1 (en) | Compounds and methods | |
| OA17199A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. |